Drug General Information
Drug ID	D03GII
Former ID	DIB001670
Drug Name	SR-26831
Drug Type	Small molecular drug
Indication	Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]		Terminated	[544831]
Company	Sanofi
Structure		Download 2D MOL 3D MOL
Formula	C19H23ClNO3S+
Canonical SMILES	c1(sc2c(c1)C[N+](Cc1c(Cl)cccc1)(CC2)[O-])OC(=O)C(C)(C)C
CAS Number	CAS 139995-67-8
PubChem Compound ID	132270
Target and Pathway
Target(s)	Leukocyte elastase	Target Info	Modulator	[528753]
KEGG Pathway	Transcriptional misregulation in cancer
	Systemic lupus erythematosus
Pathway Interaction Database	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
	C-MYB transcription factor network
Reactome	Collagen degradation
	Degradation of the extracellular matrix
	Activation of Matrix Metalloproteinases
WikiPathways	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
	Human Complement System
	Degradation of collagen
References
Ref 544831	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001260)
Ref 528753	Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor. J Pharmacol Exp Ther. 1992 Feb;260(2):809-16.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.